This is a multiple-dose, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of LY3041658 in patients with neutrophilic skin diseases. Volunteers with neutrophilic skin disease are needed to participate in a research study to assess the safety, tolerability, and activity of an investigational drug that is being developed as a potential treatment for plaque psoriasis, palmoplantar pustulosis, or hidradenitis suppurativa.
This is a randomised phase III double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC). Regorafenib (BAY 73-4506) is an investigational oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-ß), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases, and has shown activity in other solid tumours. Regorafenib was shown to prolong PFS across all regions/subgroups in INTEGRATE I The general aim of this study is to determine if regorafenib improves overall survival in refractory AGOC.
This research study is for people with advanced liver cancer who have never received systemic medicine (affecting the entire body) for advanced liver cancer. This is a randomized, open-label Phase 3 study to determine whether treatment with vaccinia virus-based immunotherapy (Pexa-Vec) followed by sorafenib can slow the progression of advanced liver cancer and improve quality of life compared to treatment with sorafenib alone.
This study is hypothesized as perioperative naloxone infusion and tramacet provides adequate analgesia in elderly patients undergoing total knee/hip arthroplasty and is associated with 80% reduction in opioid use and reduced opioid-induced side effects. The primary objective is to determine opioid use during combined use of oral tramacet and naloxone infusion perioperatively in elderly patients (70 yrs and older) having elective knee/ hip arthroplasty under spinal anesthesia. Secondary objectives are to determine the incidence of VAS scores ≥4 and adverse effects such as nausea, vomiting, sedation, respiratory depression, pruritus, confusion, and time of independent mobilization.
The purpose of this study is to determine whether pirfenidone is safe and effective in the treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary fibrosis with anti-MPO associated vasculitis.
University of Minnesota - Clinical and Translational Science Institute is conducting a Case Control Observational study in 100 participants in order to examine the effects of cystic fibrosis (CF) and cystic fibrosis related diabetes (CFRD) on brain structure and function.
Yi Yang, First Hospital of Jilin University is conducting a Single Group Assignment Interventional Trial in 1000 participants in order to determine the efficacy and safety of remote ischemic conditioning for essential hypertension.
Stanford University is conducting a Single Group Assignment Interventional Trial in 250 participants in order to understand the utility and effectiveness of approximate number sense as a training tool in children to enhance complex mathematics ability.
Boston Children’s Hospital is conducting a Randomized Interventional Trial in 200 participants in order to evaluate the effect and impact of a technology which creates a virtual reality (VR), personalized representation of a patient's endoscopic findings in comparison our standard practice (SP). Our study will compare the level of knowledge, understanding and satisfaction the patient and family have between those receiving SP and those receiving both SP and VR.